LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LEXICON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.55+0.03 (+1.97%)
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.13 (+9.15%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LEXICON PHARMACEUTICALS, INC. saw revenue fall 29.0% to $41.47M over the twelve months to Jun 30, 2026. Free cash flow was -$67.85M.
Revenue
$41.47M
-29.0% vs. a year earlier
Operating income
-$54.50M
TTM Q2 2026
Free cash flow
-$67.85M
FY2025
EPS, diluted
-$0.15
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $678.36M
- P/E ratio
- –
- Price to sales
- 16.36
- Price to book
- 3.89
- Dividend yield
- –
- Free cash flow yield
- -10.00%
Fundamentals
- Revenue
- $41.47M
- Net income
- -$61.12M
- EPS, diluted
- -$0.15
- Free cash flow
- -$67.85M
- Book value per share
- $0.40
- Diluted shares
- 438M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$41.47M-29.0% YoY
Gross profit
$41.11M-29.1% YoY
Operating income
-$54.50M
Net income
-$61.12M
EPS, diluted
-$0.15
Free cash flow
–
Reported periodTrailing twelve months